Scrip is part of the Informa Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Novo Nordisk AS

www.novonordisk.com

Latest From Novo Nordisk AS

Impact Of Higher Part D Donut Hole Discounts Beginning To Show: Xarelto Sales Down 19%

Performance of Johnson & Johnson’s blockbuster cardiovascular drug is one of the first prominent examples of how the 2019 increase in the discount from 50% to 70% is playing out in the market.

Reimbursement Medicare

ICER 2020 Priorities Include Drugs For Ulcerative Colitis, NASH And Gene Therapies

The Institute for Clinical and Economic Review has a full agenda planned for 2020, starting with potential new oral drugs for migraine.

Comparative Effectiveness Gene Therapy

Heralding Change: Product Pipeline Advances To Watch Out For In Q3

Key events that could move innovative product candidates nearer the market in the third quarter of 2019 are highlighted in a new Biomedtracker/Meddevicetracker report.

Approvals Clinical Trials

Novo Nordisk To Start Phase III Trials Of Hemophilia Contender Concizumab In 2H

Subcutaneous bypassing agent concizumab will progress to Phase III after positive late-stage trials shows promise for all patients with hemophilia.

Clinical Trials Blood & Coagulation Disorders
See All

Company Information

Advertisement
Advertisement
UsernamePublicRestriction

Register